The SwissPrEPared Study
Launched by UNIVERSITY OF ZURICH · Mar 25, 2019
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The SwissPrEPared Study is a research project designed to follow individuals who are interested in taking Pre-exposure Prophylaxis (PrEP) to prevent HIV. This study is part of a larger program and will last for three years, gathering information from participants across Switzerland. The goal is to better understand how PrEP works in real life and to support those who choose this option for HIV prevention.
To be eligible for the study, participants need to be at least 16 years old, HIV negative, and already part of the SwissPrEPared program. Unfortunately, those who might struggle to follow the study's procedures, such as due to language barriers or certain mental health issues, cannot participate. If you join the study, you can expect regular check-ins and support as you use PrEP, helping researchers learn more about its effectiveness and how it can help keep people healthy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participation in the SwissPrEPared program
- • Aged ≥16 years
- • HIV negative
- Exclusion Criteria:
- • Individuals unable to follow program procedures (e.g. language barriers, mental or psychiatric disorders)
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baden, Aargau, Switzerland
Bern, , Switzerland
Chur, , Switzerland
Winterthur, , Switzerland
Zürich, , Switzerland
Aarau, Aargau, Switzerland
Geneva, , Switzerland
Münsterlingen, Thurgau, Switzerland
Chur, Graubünden, Switzerland
Zurich, , Switzerland
Delémont, Jura, Switzerland
Olten, Solothurn, Switzerland
Winterthur, Zürich, Switzerland
Basel, Basel Stadt, Switzerland
Lugano, Ticcino, Switzerland
Lausanne, Waadt, Switzerland
Lausanne, Waadt, Switzerland
Bern, , Switzerland
Geneva, , Switzerland
Saint Gallen, , Switzerland
Zürich, , Switzerland
Zürich, , Switzerland
Neuchâtel, , Switzerland
Thun, Bern, Switzerland
Basel, Basel Stadt, Switzerland
Basel, Basel Stadt, Switzerland
Basel, Basel Stadt, Switzerland
Biel, Bern, Switzerland
Cottens, Fribourg, Switzerland
Gland, Vaud, Switzerland
Lausanne, Vaud, Switzerland
Lausanne, Vaud, Switzerland
Lausanne, Vaud, Switzerland
Lausanne, Vaud, Switzerland
Renens Vd, Vaud, Switzerland
Geneva, , Switzerland
Geneva, , Switzerland
Geneva, , Switzerland
Luzern, , Switzerland
Saint Gallen, , Switzerland
Zürich, , Switzerland
Zürich, , Switzerland
Zürich, , Switzerland
Zürich, , Switzerland
Patients applied
Trial Officials
Benjamin Hampel, MD
Principal Investigator
University of Zurich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials